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DUSP-1Sphingosine 1-phosphate (S1P), a bioactive sphingolipid elevated in asthmatic airways, is increasingly recognized
as playing an important role in respiratory disease. S1P activates receptor-mediated signaling to modulate diverse
cellular functions and promote airway inﬂammation. Althoughmany of the stimulatory pathways activated by S1P
have been delineated, especially mitogen-activated protein kinases (MAPK), the question of whether S1P exerts
negative feedback control on its own signaling cascade via upregulation of phosphatases remains unexplored.
We show that S1P rapidly and robustly upregulates mRNA and protein expression of the MAPK deactivator–
MAPK phosphatase 1 (MKP-1). Utilizing the pivotal airway structural cell, airway smooth muscle (ASM), we con-
ﬁrm that S1P activates all members of the MAPK family and, in part, S1P upregulates MKP-1 expression in a p38
MAPK-dependent manner. MKP-1 is a cAMP response element binding (CREB) protein-responsive gene and
here, we reveal for the ﬁrst time that an adenylate cyclase/PKA/CREB-mediated pathway also contributes to
S1P-inducedMKP-1. Thus, by increasingMKP-1 expression via parallel p38MAPK- and CREB-mediated pathways,
S1P temporally regulates MAPK signaling pathways by upregulating the negative feedback controller MKP-1. This
limits the extent and duration of pro-inﬂammatoryMAPK signaling and represses cytokine secretion in ASM cells.
Taken together, our results demonstrate that S1P stimulates both kinases and the phosphatase MKP-1 to control
inﬂammation in ASM cells and may provide a greater understanding of the molecular mechanisms responsible
for the pro-asthmatic functions induced by the potent bioactive sphingolipid S1P in the lung.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The bioactive sphingolipid sphingosine 1-phosphate (S1P) plays
an important role in a number of diseases typiﬁed by inﬂammation,
including respiratory disorders such asthma [1,2]. In 2001, we dem-
onstrated that S1P was elevated in human asthma [3] and over the
past decade S1P has been shown to promote development of a
pro-asthmatic and pro-remodeling phenotype in airway cells in
vitro, ex vivo and in vivo. S1P regulates key airway functions such as
contraction [4,5], cytokine secretion [3], leukocyte recruitment [6],
and airway cell hyperplasia [7]. Moreover, a clear pathophysiologic
role has been revealed by recapitulation of asthmatic phenotype by
administration of S1P in mouse models of human disease [8]. Thus,
S1P has emerged as an important mediator responsible for airway in-
ﬂammation and hyperresponsiveness in asthma. As S1P is anMP response element binding;
signal-regulated kinase; IL-6,
ogen-activated protein kinase;
A, protein kinase A; SEM, stan-
TNFα, tumor necrosis factor α
+61 2 93514391.
mmit).
l rights reserved.attractive target for the development of new pharmacotherapeutic
strategies, a greater understanding of S1P-mediated signaling in
clinically-relevant airway cells is warranted.
S1P regulates myriad cellular functions due to the broad nature of
the family of cognate receptors — S1P receptors 1–5 (S1P1–5)
(reviewed in [9–13]). S1P receptors are G protein-coupled receptors
coupled to a range of heterotrimeric G proteins co-ordinating diverse
downstream signaling pathways in a species- and cell type-speciﬁc
manner. Our studies utilize the pivotal airway cell–airway smooth
muscle (ASM). ASM cells express S1P1–5 [3] and we and others have
explored some of the signaling pathways activated in ASM upon ex-
ogenous addition of S1P. S1P acts via Gi-coupled S1P receptors to ac-
tivate members of the mitogen-activated protein kinase (MAPK)
family [14,15], and we showed that S1P increases production of the
second messenger cAMP in a Gs-coupled manner [3]. To date, wheth-
er S1P controls the extent and duration of its own signaling cascade
by upregulating the MAPK phosphatase 1 (MKP-1) has not been ex-
plored in ASM cells, or any other cell type.
MKP-1 is a potent MAPK deactivator that plays an important neg-
ative feedback role in a wide range of inﬂammatory cells [16,17]. In
ASM, we recently reported that stimulation with tumor necrosis fac-
tor α (TNFα) increases MKP-1 upregulation via a p38 MAPK manner.
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restrain MAPK-mediated pro-inﬂammatory signaling pathways and
cytokine secretion [18]. Whether S1P activates a comparable negative
feedback loop is unknown at present. Therefore, the aim of this study
was to examine for the ﬁrst time whether S1P upregulates MKP-1, the
underlying molecular mechanism and the impact on cytokine secre-
tion from ASM cells. We show that S1P-induces MKP-1 expression
via activation of parallel p38 MAPK and CREB-mediated pathways
and MKP-1 serves to restrain pro-inﬂammatory MAPK signaling and
synthetic function of ASM cells. In this way, MKP-1 acts as a negative
feedback effector and allows S1P to control the extent and duration of
its own inﬂammatory signaling cascade.2. Materials and methods
2.1. Cell culture
Human bronchi were obtained from patients undergoing surgical
resection for carcinoma or lung transplant donors in accordance
with procedures approved by the Sydney South West Area Health
Service and the Human Research Ethics Committee of the University
of Sydney. ASM cells were dissected, puriﬁed and cultured as previ-
ously described by Johnson et al. [19]. A minimum of three different
ASM primary cell lines was used for each experiment.
Unless otherwise speciﬁed, all chemicals used in this study were
purchased from Sigma-Aldrich (St. Louis, MO).2.2. Western blotting
Western blotting was performed using rabbit monoclonal or poly-
clonal antibodies against phosphorylated (Thr180/Tyr182) and total
p38 MAPK, phosphorylated (Thr202/Tyr204) and total extracellular
signal-regulated kinase (ERK), phosphorylated (Thr183/Tyr185) and
total c-Jun N-terminal kinase (JNK), phosphorylated (Ser133) and
total cAMP response element binding (CREB) (all from Cell Signaling
Technology, Danvers, MA). MKP-1 was quantiﬁed by Western blot-
ting using a rabbit polyclonal antibody against MKP-1 (C-19: Santa
Cruz Biotechnology, Santa Cruz, CA), compared to α-tubulin used as
the loading control (mouse monoclonal IgG1, DM1A: Santa Cruz Bio-
technology, Santa Cruz, CA). Primary antibodies were detected with
goat anti-mouse or anti-rabbit HRP‐conjugated secondary antibodies
(Cell Signaling Technology) and visualized by enhanced chemilumi-
nescence (PerkinElmer, Wellesley, MA).2.3. Real-time RT-PCR
Total RNAwas extracted using the RNeasyMini Kit (Qiagen Australia,
Doncaster, VIC, Australia) and reverse transcription was performed by
using the RevertAid First Strand cDNA Synthesis Kit (Fermentas Life
Sciences, Hanover, MD) as per the manufacturer's protocol.
MKP-1 mRNA levels were measured using real-time RT-PCR on an
ABI Prism 7500 (Applied Biosystems, Foster City, CA) with the DUSP1
(Hs00610256_g1) TaqMan® Gene Expression Assay and the eukaryotic
18S rRNA endogenous control probe (Applied Biosystems) subjected to
the following cycle parameters: 50 °C for 2 min, 1 cycle; 95 °C for
10 min, 1 cycle; 95 °C for 15 s, 60 °C for 1 min, 40 cycles.2.4. ELISAs
Cell supernatants were collected and stored at−20 °C for later analy-
sis by ELISA. Interleukin 6 (IL-6) ELISAs were performed according to the
manufacturer's instructions (BD Biosciences Pharmingen, San Diego, CA).2.5. MKP-1 overexpression
ASM cells were transiently transfected with the MKP-1 expression
vector pCMV-Flag-MKP-1 [20] generously provided by Andrew R.
Clark (Kennedy Institute of Rheumatology, Imperial College London)
using the methods established in our previous publication [21]. Cells
were stimulated with S1P (1 μM) for 24 h before supernatants were
removed for IL-6 protein measurement by ELISA.
2.6. Statistical analysis
Statistical analysis was performed using the Student's unpaired t
test. P valuesb0.05 were sufﬁcient to reject the null hypothesis for
all analyses.
3. Results
3.1. Temporal activation of MAPKs and upregulation of MKP-1 by S1P
To demonstrate the temporal activation of MAPK family members
by S1P and the subsequent upregulation of MKP-1 protein,
growth-arrested ASM cells were treated with S1P for up to 1 h and
MAPK phosphorylation was quantiﬁed by Western blotting. As
shown in Fig. 1A, S1P stimulates a rapid, but transient, activation of
all three MAPK family members within 5 min of stimulation with
S1P. Although the temporal kinetics of MAPK phosphorylation can
vary slightly between primary cultures, in general MAPK phosphory-
lation appears to peak at 10–30 min before returning to baseline
levels by 60 min. Interestingly, the decline in MAPK activation is mir-
rored by upregulation of MKP-1 protein. This timing is suggestive of a
negative feedback mechanism in human ASM cells, recently identiﬁed
for TNFα-induced MKP-1 [18] whereby inﬂammatory stimuli activate
kinases (MAPKs) as well as their own phosphatases (MKP-1), in order
to regulate the extent and duration of signal transduction.
To determine the MAPK responsible for S1P-induced upregulation
of MKP-1 we performed a series of experiments where ASM cells
were pretreated with pharmacological inhibitors of p38 MAPK, ERK,
and JNK signaling pathways and the resultant effect on S1P-induced
MKP-1 upregulation was assessed by Western blotting. As shown in
Fig. 1B, pretreatment with the p38 MAPK inhibitor SB203580
inhibited S1P-induced p38 MAPK phosphorylation at 30 min and cor-
respondingly repressed MKP-1 protein upregulation at both 30 and
60 min. Although PD98059 and SP600125 were effective inhibitors
of ERK and JNK phosphorylation at 30 min, the protein levels of
MKP-1 observed after stimulation with S1P were not repressed by
either inhibitor (Fig. 1B). These results suggest that S1P induces
upregulation of MKP-1 in a p38 MAPK-mediated manner and this
was conﬁrmed by densitometric analysis (Fig. 1C).
3.2. MKP-1 expression is cAMP/CREB-responsive and S1P induces CREB
phosphorylation to upregulate MKP-1 expression via an adenylate
cyclase/PKA/CREB-mediated pathway
S1P acts on the S1P receptor family to stimulate myriad cell signal-
ing pathways [9–13]. A number of S1P receptors (i.e. S1P2 and S1P3)
are coupled to adenylate cyclase [10,11]. In this way, S1P stimulation
increases the important second messenger cAMP. In 2001 [3] we
demonstrated that S1P acts via S1P receptors to increase cAMP levels
in ASM cells. As cAMP activates CREB signaling pathways and MKP-1
is a CREB-responsive gene [22], we nowwish to ascertain the involve-
ment of the adenylate cylase/cAMP-mediated cellular signaling path-
way in the upregulation of MKP-1 in ASM cells.
Firstly, to show that adenylate cyclase stimulation upregulates
MKP-1 in ASM cells, we pretreated cells for 30 min with the adenyl-
ate cyclase activator – forskolin – and then examined MKP-1 mRNA
and protein expression in the absence and presence of S1P treatment
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Fig. 1. Temporal activation of MAPKs and upregulation of MKP-1 by S1P. (A) Growth-arrested ASM cells were stimulated with S1P (1 μM) for 0, 5, 10, 30 and 60 min. (B)
Growth-arrested ASM cells were pretreated for 30 min with vehicle, or the MAPK inhibitor PD98059 (10 μM), SB203580 (1 μM) or SP600125 (10 μM), then stimulated with
S1P for 30 min and 60 min. Western blotting was performed using speciﬁc antibodies against phosphorylated (Thr180/Tyr182) and total p38 MAPK, phosphorylated (Thr202/
Tyr204) and total ERK, phosphorylated (Thr183/Tyr185) and total JNK, and MKP-1. α-Tubulin was used as the loading control. (A, B) Results are representative Western blots
from n=5 primary ASM cell lines and (C) demonstrates densitometric analysis where results are expressed as % S1P-induced MKP-1 protein upregulation at 60 min. Statistical
analysis was performed using the Student's unpaired t test where ∞ denotes signiﬁcant inhibition by SB203580 (Pb0.05) (mean+SEM values from n=5 primary ASM cell lines).
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icantly upregulatedMKP-1mRNA expression in ASM cells by 26.8.0±
3.0-fold, compared to vehicle-treated cells (Pb0.05). Interestingly,
forskolin and S1P treatment in combination had an additive effect on
MKP-1 mRNA expression in ASM cells. As demonstrated in Fig. 2A,
forskolin pretreatment signiﬁcantly increased S1P‐induced mRNA ex-
pression from 19.6±3.0-fold to 47.6±4.2-fold (Pb0.05). Adenylate cy-
clase activation also upregulated MKP-1 protein in similar manner; as
shown in Fig. 2B, forskolin treatment alone increased MKP-1 and en-
hanced S1P-induced upregulation.Secondly, to demonstrate that cAMP increases MKP-1 expression
in ASM cells, we treated cells for 1 h with a cell-permeable cAMP
analogue — dibutyryl cAMP. As shown in Fig. 2C, dibutyryl cAMP sig-
niﬁcantly increased MKP-1 mRNA levels by 3.3±0.2-fold, compared
to vehicle-treated cells (Pb0.05). This was associated with CREB acti-
vation, as dibutyryl cAMP increased CREB Ser133 phosphorylation (at
30 min) with a subsequent increase in MKP-1 protein upregulation
after 60 min stimulation with dibutyryl cAMP (Fig. 2D).
Because we demonstrated that MKP-1 expression is adenylate
cyclase/cAMP/CREB-responsive in ASM cells we now wished to
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quentMKP-1 upregulation after stimulationwith S1P. As demonstrated
in Fig. 2E, S1P robustly and potently induces CREB phosphorylation (at
Ser133) as early as 5 min and this activation was sustained for the
60 min time period examined. Fig. 2E also shows S1P-induced MKP-1
upregulation. To link S1P-induced activation of the CREB-signalingFig. 2.MKP-1 expression is cAMP/CREB-responsive and S1P induces CREB phosphorylation t
(A, B) Growth-arrested ASM cells were pretreated for 30 min with vehicle or forskolin (10 μ
treated with vehicle or dibutyryl cAMP (1 mM) for 30 and 60 min. (E) Growth-arrested ASM
ASM cells were pretreated for 60 min with vehicle or H-89 (10 μM), then treated with veh
expression was quantiﬁed by real-time RT-PCR and results were expressed as fold increase
the Student's unpaired t test where * denotes a signiﬁcant increase in MKP-1 mRNA expre
by forskolin (Pb0.05) (mean+SEM values from n=3 primary ASM cell lines). (B, D, E,
MKP-1 protein (compared to α-tubulin as a loading control) was quantiﬁed by Western bl
cell lines.pathway with MKP-1 upregulation we pretreated cells with H-89, a
pharmacological inhibitor known to attenuate activity of protein kinase
A (PKA) — a key kinase responsible for phosphorylation of CREB at
Ser133. Although H-89 is relatively non-speciﬁc, our results suggest
that S1P induces CREB phosphorylation to upregulate MKP-1 expres-
sion via a PKA/CREB-mediated pathway. As shown in Fig. 2F, H-89o upregulate MKP-1 expression via an adenylate cyclase/PKA/CREB-mediated pathway.
M), then treated with vehicle or S1P for 60 min. (C, D) Growth-arrested ASM cells were
cells were stimulated with S1P (1 μM) for 0, 5, 10, 30 and 60 min. (F) Growth-arrested
icle or S1P for 60 min. Dibutyryl cAMP was assessed in parallel. (A, C) MKP-1 mRNA
compared to vehicle-treated cells at 60 min. Statistical analysis was performed using
ssion and § denotes signiﬁcant upregulation of S1P-induced MKP-1 mRNA expression
F) CREB phosphorylation at Ser133 (compared to total CREB) and/or upregulation of
otting, where (B, D, E, F) illustrate representative Western blots of n=3 primary ASM
Fig. 2 (continued).
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MKP-1 upregulation at 60 min.
3.3. S1P increases MKP-1 expression via parallel p38 MAPK- and
CREB-mediated pathways
Taken together our data shows that S1P-inducedMKP-1 upregulation
is associated with activation of both p38 MAPK- and CREB-mediated
pathways. In cell types apart from ASM, CREB activation has been dem-
onstrated as downstream of p38MAPK. Thus, two possible explanations
exist: (i) S1P-induces CREB phosphorylation in a p38 MAPK-dependent
manner; (ii) S1P induces MKP-1 expression via parallel p38 MAPK-
and CREB-mediated pathways. To exclude the former possibility we
pretreated ASM cells with the p38 MAPK inhibitor SB203580 and exam-
ined the effect on S1P-induced p38MAPK and CREB phosphorylation. As
shown in Fig. 3A, SB203580 effectively blocked S1P-induced p38 MAPK
phosphorylation. In contrast, S1P-induced CREB activation was unaffect-
ed by pretreatment with the p38 MAPK inhibitor. These results are in
support of parallel p38 MAPK and CREB-mediated pathways underlying
S1P-induced MKP-1 upregulation.
To conﬁrm this assertion, we pretreated ASM cells with inhibitors of
thep38MAPK andPKA/CREB-mediated pathways alone and in combina-
tion and measured the effects on S1P-induced MKP-1 mRNA expression
and protein upregulation. As shown in Fig. 3B, blocking the p38 MAPK
pathway signiﬁcantly inhibited MKP-1 mRNA expression, reducing the
level of MKP-1 stimulated by S1P from 16.8±2.5-fold to 10.3±
0.8-fold when cells were pretreated with SB203580 (Pb0.05). Inhibiting
PKA with H-89 also effectively repressed S1P-induced MKP-1 mRNA (to
9.3±0.8-fold: Pb0.05). Importantly,whenboth inhibitorswere added in
combination there was a signiﬁcantly greater degree of inhibition than
achieved with either inhibitor added alone (6.6±0.3-fold; Pb0.05).
The effect of the inhibitors on S1P-induced MKP-1 protein (Fig. 3C and
D)was in accordwith themRNA results. Densitometric analysis revealed
that the combination of both inhibitors repressed S1P-induced MKP-1protein upregulation by 44.6±2.3% and had a signiﬁcantly greater re-
pressive effect than either inhibitor alone (Fig. 3D: Pb0.05). Taken to-
gether our data indicates that S1P activates dual p38 MAPK-and
CREB-mediated signaling pathways to induce MKP-1 expression.
3.4. MKP-1 is a negative feedback effector that represses S1P-induced
p38 MAPK and ERK-mediated signaling and IL-6 secretion
We have previously reported that S1P induces secretion of the cyto-
kine IL-6 from ASM cells [3]. To determine whether MAPK-mediated
signaling pathways contribute to S1P-induced IL-6 secretion ASM cells
were pretreated with inhibitors of the p38 MAPK, ERK, and JNK path-
ways prior to stimulation with S1P, using SB203580, PD98059,
and SP600125, respectively. As shown in Fig. 4A, inhibition of p38
MAPK and ERK signiﬁcantly inhibited S1P-induced IL-6 secretion
(Pb0.05). There was no effect of JNK inhibition. These results
suggest that S1P-induced IL-6 secretion from ASM cells is p38
MAPK- and ERK-dependent.
To conﬁrm that S1P temporally regulates MAPK signaling path-
ways by upregulating the negative feedback controller – MKP-1 –
we blocked MKP-1 upregulation with the pharmacological inhibitor,
triptolide [18,23,24] and observed the effect on p38 MAPK and ERK
phosphorylation. As demonstrated in Fig. 4B, triptolide pretreatment
completely repressed S1P-induced MKP-1 protein. Where we had
previously demonstrated that MAPK phosphorylation declines at 30
and 60 min (also see Fig. 1A), in the absence of MKP-1 p38 MAPK
and ERK phosphorylation continues in an unrestrained manner. In
this way, MKP-1 controls the extent and duration of S1P-induced sig-
naling and has a signiﬁcant impact on cytokine secretion from ASM
cells. This is demonstrated in Fig. 4C, where S1P-induced IL-6 secre-
tion from ASM cells was signiﬁcantly repressed in cells that had
been transfected with an MKP-1 overexpression vector, compared
to cells transfected with vector control (Pb0.05). Taken together,
our results suggest that S1P-induced MKP-1 serves to restrain
Fig. 3. S1P increases MKP-1 expression via parallel p38 MAPK- and CREB-mediated pathways. (A) Growth-arrested ASM cells were pretreated for 30 min with vehicle or 1 μM
SB203580, prior to stimulation with S1P (1 μM) for 0, 5, 10, 30 and 60 min. (B, C, D) Growth-arrested ASM cells were pretreated for 60 min with vehicle or H-89 (10 μM), or
for 30 min with 1 μM SB203580, prior to stimulation with S1P (1 μM) for 60 min, compared to vehicle control. (A, C, D) p38 phosphorylation at Thr180/Tyr182 (compared to
total p38 MAPK), CREB phosphorylation at Ser133 (compared to total CREB), or upregulation of MKP-1 protein (compared to α-tubulin as a loading control) was quantiﬁed byWestern
blotting, where (A, C) illustrate representative Western blots and (D) demonstrates densitometric analysis where results are expressed as % S1P-induced MKP-1 protein upregulation at
60 min (mean+SEMvalues fromn=4primary ASMcell lines). (B)MKP-1mRNAexpressionwasquantiﬁedby real-time RT-PCR and resultswere expressed as fold increase compared to
vehicle-treated cells at 0 min (mean+SEM values from n=3 primary ASM cell lines). Statistical analysis was performed using the Student's unpaired t test where * denotes a signiﬁcant
increase in MKP-1 mRNA expression, § denotes signiﬁcant inhibition by SB203580 or H-89, and ∞ indicates a signiﬁcant effect of H89 and SB203580 in combination, compared to either
inhibitor added alone (Pb0.05).
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cells.
4. Discussion
S1P is an important pathophysiological mediator found elevated in
human asthma that drives the development of a pro-inﬂammatory
and pro-remodeling phenotype in the airway. Recent research has
highlighted the prospect of targeting S1P as potential therapy and in
the current study we illustrate the endogenous anti-inﬂammatorymechanisms that are activated by S1P itself to exert regulatory control
over cellular signaling. We discover that S1P, like other stimuli,
upregulates the phosphatase MKP-1 that acts in a negative feedback
manner to repress MAPK-mediated pathways and cytokine secretion
in ASM cells. In this way, MKP-1 serves as an important negative feed-
back mechanism to limit the pro-inﬂammatory response to S1P in air-
way cells.
In 2001 [3] we demonstrated that S1P modulates ASM functions
that promote inﬂammation and remodeling in asthma. We demon-
strated that cAMP levels are increased via activation of the Gs-coupled
Fig. 4.MKP-1 is a negative feedback effector that represses S1P-induced p38 MAPK and ERK-mediated signaling and IL-6 secretion. (A) Growth-arrested ASM cells were pretreated
for 30 min with vehicle, 1 μM SB203580, or 10 μM PD98059 to inhibit p38 MAPK and ERK, respectively, then stimulated with 1 μM S1P for 24 h. IL-6 secretion was measured by
ELISA. Data are expressed as % S1P-induced IL-6 secretion (where IL-6 protein secreted in response to 1 μM S1P was 1711.7±193.6 pg/ml (data are mean±SEM)). Statistical anal-
ysis was performed using the Student's unpaired t test, where ∞ denotes signiﬁcant inhibition (Pb0.05). Data are mean+SEM values from n=11 primary ASM cell lines.
(B) Growth-arrested ASM cells were pretreated for 30 min with vehicle or the MKP-1 inhibitor triptolide (1 μM) prior to stimulation with S1P (1 μM) for 0, 5, 10, 30 and
60 min. Western blotting was performed using speciﬁc antibodies against MKP-1 (compared to α-tubulin used as the loading control), phosphorylated (Thr180/Tyr182) and total
p38 MAPK, phosphorylated (Thr202/Tyr204) and total ERK. Results are representative Western blots from n=3 primary ASM cell lines. (C) ASM cells were transiently transfected
with a MKP-1 expression vector, or empty vector control, stimulated for 24 h with S1P (1 μM), before IL-6 secretion was measured by ELISA. Data are expressed as %
S1P-induced IL-6 secretion in cell transfected with empty vector alone and statistical analysis was performed using the Student's unpaired t test, where ∞ denotes signiﬁcant in-
hibition (Pb0.05). Data are mean+SEM values from n=6 primary ASM cell lines.
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duces IL-6 secretion. We now extend these studies to show that S1P
rapidly and robustly stimulates CREB phosphorylation at Ser133.
Moreover, all members of the MAPK family are activated by S1P in a
temporally distinct manner, but only p38 MAPK and ERK in particular
contribute to S1P-induced IL-6 secretion. In cell types apart from
ASM, the MAPK deactivator MKP-1 has been reported to be induced
by CREB- and MAPK-mediated pathways [25–27]. Thus, in this
paper we report that S1P upregulates MKP-1, illustrate the underly-
ing molecular mechanisms responsible and highlight the impact on
cytokine secretion from ASM cells.
MKP-1 is the archetypal member of the MKP family, also
known as DUSPs (dual-speciﬁcity phosphatases). MKPs directdual dephosphorylation of MAPKs in a cell-type speciﬁc manner.
MAPK-mediated cellular function is regulated by both strength
and duration of MAPK phosphorylation. This signaling must be
strictly controlled to modulate functional outcome. This crucial
negative feedback control is achieved by the MKPs, as they are
immediate-early genes [28] known to be capable of rapid expression
and upregulation. We show that S1P rapidly and robustly upregulates
both MKP-1 mRNA expression and protein upregulation within 1 h
after stimulation; although the resultant MKP-1 upregulation is tran-
sient and returns to baseline levels by 2 h (data not shown). Dual path-
ways are responsible for S1P-induced MKP-1 expression in ASM cells.
Upregulation was shown, in part, to be cAMP-mediated and occurred
via the PKA/CREB pathway. Notably, the human MKP-1 promoter is
1665W. Che et al. / Biochimica et Biophysica Acta 1823 (2012) 1658–1665known to contain two cis-acting cAMP response elements [25,26].
CREB-mediated upregulation occurred in parallel with p38 MAPK-
mediated expression, as pharmacological inhibition of the p38 MAPK-
mediated pathway with SB203580 attenuated S1P-iduced MKP-1 gene
expression and protein expression; conﬁrming earlier studies in alveolar
macrophages [29] and our recent study in ASM cells [18].
Therefore, in this paper we have underscored the important neg-
ative feedback role played by MKP-1 and determined that S1P con-
comitantly stimulates both inﬂammatory (CREB and MAPKs) and
the anti-inﬂammatory (phosphatase MKP-1) to control synthetic
function in ASM cells. Thus, S1P, like other inﬂammatory stimuli in
ASM cells (e.g. TNFα: (20)), induces MKP-1 to serve as a negative
feedback effector. We show for the ﬁrst time that S1P-induced IL-6
secretion is mediated by p38 MAPK- and ERK-dependent pathways
and observe that p38 MAPK and ERK phosphorylation continues in
an unrestrained fashion when MKP-1 is not present to “switch
them off” at the right time. Moreover, MKP-1 overexpression re-
strains S1P-induced cytokine secretion. In summary, in this manu-
script we have demonstrated that the MAPK responsible for
S1P-induced MKP-1 upregulation is p38 MAPK. Once upregulated,
MKP-1 can then serve as a MAPK deactivator and can dephosphory-
late members of the MAPK family in a cell-type and species-speciﬁc
manner. Thus, in this way, the identity of the MAPKs responsible for
MKP-1 upregulation and those MAPKs that can be dephosphorylated
can differ.
Collectively, our results provide further support for the important
negative feedback role played by the endogenous anti-inﬂammatory
protein – MKP-1 – in human ASM cells. By inducing MKP-1 expres-
sion via parallel p38 MAPK- and CREB-mediated pathways, the bio-
logically active sphingolipid S1P controls the extent and duration of
pro-inﬂammatory cellular signaling and regulates ASM synthetic
function. This raises the possibility that this inherent feedback loop
via MKP-1 activation might be exploited to restrict S1P action in asth-
ma in the future.
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